Pazopanib
- PDF / 170,212 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 93 Downloads / 163 Views
1 S
Pazopanib Gastrointestinal toxicity manifested as diarrhoea and hypothyroidism following compassionate use in relapsed osteosarcoma: case report
In a retrospective study of 2 patients, an approximately 34-year-old woman (case 2) was described, who developed gastrointestinal (GI) toxicity in the form of diarrhoea and hypothyroidism during treatment with pazopanib on a compassionate use basis for relapsed osteosarcoma [OS; route, dosage, times to reactions onsets and outcomes of ADRs not stated]. The woman, who was diagnosed with left femur OS at the age of 25 years, was treated with methotrexate, doxorubicin and cisplatin, followed by amputation and unspecified neoadjuvant chemotherapy. Subsequently, she remained in remission for 6 years; however, in January 2013, she presented with two lung masses, which were resected twice, and she also received systemic chemotherapy with ifosfamide and etoposide, followed by adjuvant radiation. After 2 years, while she was pregnant, she developed recurrence at the same site. Therefore, she was treated with gemcitabine and docetaxel, to which she showed a partial response. However, after 10 months, treatments were discontinued due to pleural effusion and peripheral oedema [aetiologies unknown]. Three months later, at the age of ~34 years, she presented with a progressive tumour in the pleural base (relapsed OS), for which she started receiving pazopanib on a compassionate use basis. She exhibited response to pazopanib, with stable size of tumour and increased homogeneity, which suggested tumour necrosis. However, she developed GI toxicity including diarrhea and hypothyroidism secondary to pazopanib. Therefore, the woman’s treatment with pazopanib was discontinued after 3 months. Within 1 week of discontinuation of pazopanib, the lesions increased by 17% in size. Later, she had multiple relpases. At the time of report (18 months following discontinuation of pazopanib), she was alive. Elete KR, et al. Response to Pazopanib in Patients With Relapsed Osteosarcoma. Journal of Pediatric Hematology/Oncology 42: e254-e257, No. 4, May 2020. Available from: 803519382 URL: http://doi.org/10.1097/MPH.0000000000001375
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
